Home | Contact Us | FAQ | Search & Site Map | Link to Us
Sign In | Join | Other 45 Sites in Network
Home
Discussion Groups
General
GeneralCardiologyVisionDentistryPharmacyLaboratoryNutritionAlternative
Diseases and Disorders
AIDSAlzheimer'sArthritisAsthmaCancerBreast CancerDiabetesEpilepsyGlaucomaHepatitisHerpesLupusProstate BPHProstate CancerProstatitisSinusitisTinnitus

Medical Forum / Diseases and Disorders / Prostate Cancer / January 2007

Tip: Looking for answers? Try searching our database.

Managing Bone Metastases and Pain

Thread view: 
Enable EMail Alerts  Start New Thread
Thread rating: 
J - 13 Jan 2007 10:43 GMT
<http://www.prostatecancerfoundation.org/site/c.itIWK2OSG/b.47320/k.3A88/Managing
_Bone_Metastases_and_Pain.htm
>

Managing Bone Metastases and Pain

Prostate cancer cells that spread to the bone are known as prostate cancer
bone metastases (not bone cancer). Once they settle in the bone, the
cancer cells begin to interfere with the normal health and strength of the
bones, often leading to bone pain, fracture, or other complications that
can significantly impair one’s health.

Early detection of bone metastases can help to determine the best
treatment strategy, and can help to ward off complications caused by the
metastases.

In addition, because men with prostate cancer bone metastases often
experience painful episodes, pain management and improving quality of life
is an important part of all treatment strategies for men with bone
metastases.

Treating Metastases

An important part of prostate cancer bone metastases management is
maintaining adequate calcium and vitamin D levels and exercising
regularly. Even though none of these are treatments for bone metastases,
they will all help to maintain strong bones and help to minimize bone loss
and osteoporosis, which can make treating bone metastases more
challenging.

Radiation Therapy Targeting Bone Metastases
Men who experience pain from a bone metastasis will often be treated with
radiation targeted directly to the metastasis. This will kill the prostate
cancer cells and relieve the pain. (Note that radiation therapy used to
treat bone metastases is completely unrelated to radiation therapy that
might have been used earlier in prostate cancer treatment.)

External beam radiation therapy uses x-rays to kill the cancer cells that
have settled in the bones. This type of treatment, sometimes referred to
as spot radiation, is mapped out and planned very precisely by the
radiation oncologist to ensure that the x-rays are targeting the
metastasis and are not causing damage to the surrounding bone and muscle
tissue.

Radiopharmaceuticals, or radioactive drugs, are injected into the body
through a vein and settle in the bone metastases, at which point they
release radiation to the local area and kill the cancer cells. The two
drugs used for this procedure, samarium (Quadramet) and strontium
(Metastron), are sometimes used in combination with chemotherapy.

Bone-Targeting Agents (Bisphosphonates)
Under normal circumstances, bone cells are destroyed and created at a
constant rate. Increasing the activity of osteoblasts, cells that form new
bone cells, ultimately results in an overgrowth of bone tissue; increasing
the activity of osteoclasts, cells that destroy bone cells, ultimately
results in porous, brittle bone tissue. In men with prostate cancer bone
metastases, both of these processes occur at faster than normal rates,
leading to both an overgrowth of bone tissue and weakened and brittle
bones. The combination of these two processes makes the bones unstable,
and therefore prone to fracture.

Bisphosphonates are drugs that are designed to help reset the balance in
the bone between bone growth and bone destruction. Zoledronic acid
(Zometa) is a bisphosphonate given intravenously that can delay the onset
of complications associated with prostate cancer bone metastases and
relieve pain. It is typically given once every three weeks as a 15-minute
infusion.

Other bisphosphonates are sometimes used in men with prostate cancer to
prevent or slow bone loss while taking hormone therapy. These drugs,
alendronate (Fosamax) and risedronate (Actonel), are given in pill form,
and are also used to counteract the bone loss of osteoporosis in
postmenopausal women or in women who are taking hormone therapy for breast
cancer.

Anticipating Complications

Treatment for prostate cancer bone metastases has three goals: to slow
disease progression, to relieve pain, and, perhaps most importantly, to
avoid the complications that stem from the weakened bone caused by the
metastases.

Bone that is weakened by metastases is more prone to fracture, and because
the metastases often grow around the lower back and upper legs, hip
fractures tend to be most common. Vigilant monitoring for fractures is
common; less commonly, surgery might be considered to stabilize bones at
risk. This procedure can improve the chances of not fracturing the bones,
and therefore help to stave off other complications down the road.

The most significant complication from bone metastases is spinal cord
compression. A weakening of a vertebra by a prostate cancer bone
metastasis can result in the bones of the spinal column collapsing one on
top of the other, compressing the spinal cord housed within the bones as
well as the nerves that run out from it.

Cord compression associated with metastatic prostate cancer can cause
severe nerve damage, and possibly paralysis, if not managed immediately.
Therefore, additional medications, such as steroids, might be used for men
at high risk for a spinal cord compression, and surgery to stabilize the
weakened bones might be considered. MRI scans can also be used to better
visualize the health of the spinal column and to detect early any problems
that might occur.

The symptoms of spinal cord compression are often similar to those seen
with many other medical problems. For example, because bone metastases
typically occur around the lower back and upper legs, compression of the
spinal cord at that point can cause back pain, leg pain or weakness, or
loss of bladder or bowel control. It is therefore important to recognize
and address any symptoms as soon as possible. The earlier new fractures or
a spinal cord compression is detected, the easier it is to treat.

Managing Pain

There are three general rules of pain management to always keep in mind.

1. Don’t try to be too tough or act "macho". Untreated pain takes a toll
on the body, forcing it to expend a lot of energy fighting it.

2. There might be a very simple solution to the pain. Some very simple and
easy to take medications might be enough to ease the pain.

3. Don’t worry about becoming addicted to pain medication. The most common
reason that doctors are afraid to prescribe strong pain medications and
that people are afraid to take them is fear of addiction. But that’s
mostly because people don’t understand the differences between addiction,
physical dependence, and tolerance.

Addiction is a psychological and behavioral syndrome in which there is
continual or increasing use of a drug despite negative physical,
psychological, or social consequences. Taking pain medications to feel
healthier and stronger would seem to be exactly the opposite of addictive
behavior.

Someone who is physically dependent upon a drug will not be able to cope
with its loss if it is stopped or if the dose is lowered too rapidly, and
symptoms of withdrawal will be seen. This is why doses of strong pain
medications are usually tapered, or gradually lowered, before stopping,
giving the body a chance to adjust to its loss.

After using a certain drug for a long period of time, the body will become
tolerant to it, to the point where the drug is no longer effective. Slowly
increasing the doses over time can help to avoid the onset of tolerance,
but that’s only a temporary measure, and you’ll likely have to switch to a
medication that works in a slightly different manner before you can find
relief.

Note that every pain medication, like all other medications, has its own
set of side effects. Constipation is the most common side effect of pain
medication use; other side effects can include nausea and vomiting,
sleepiness, and confusion. Knowing which side effects to expect can help
decide how best to deal with them.
I.P. Freely - 13 Jan 2007 19:35 GMT
> <http://www.prostatecancerfoundation.org/site/c.itIWK2OSG/b.47320/k.3A88/Managing
_Bone_Metastases_and_Pain.htm
>
>
> Managing Bone Metastases and Pain

Excellent summation, but . . . what next? Does the pain become
unmanageable, and if so, what do we do about *that*?

I.P.
RML - 13 Jan 2007 20:02 GMT
My uncle passed from PCa this past summer, and was in hospice. At the
end, he had a Fentanyl patch, and was receiving liquid morphine.
Although he experienced visual hallucinations and poor ability to keep
his eyes open, he did not seem in pain.

>Excellent summation, but . . . what next? Does the pain become
>unmanageable, and if so, what do we do about *that*?
>
>I.P.
MAS - 14 Jan 2007 06:30 GMT
I know that this is a terrible disease and a fear of bones mets is
overwhelming. Excellent summation, however, I do want to point out that I
did not do or experience any of what you wrote and what others before you
wrote (maybe my day is coming, only God knows.)

In March of 1994, I had two mets to T3 and L2. After a clinical trial of
chemo for six months, the mets are gone and replaced with new bone growth.
My mets disappeared with the January 1995 scan. I have had seven scand since
then and still am "all clear."

Gourd Dancer

> <http://www.prostatecancerfoundation.org/site/c.itIWK2OSG/b.47320/k.3A88/Managing
_Bone_Metastases_and_Pain.htm
>
>
[quoted text clipped - 145 lines]
> sleepiness, and confusion. Knowing which side effects to expect can help
> decide how best to deal with them.
Just - 21 Jan 2007 17:10 GMT
Gourd,

Which chemo did you take in the clinical trial?

Just

>I know that this is a terrible disease and a fear of bones mets is
>overwhelming. Excellent summation, however, I do want to point out that I
[quoted text clipped - 157 lines]
>> sleepiness, and confusion. Knowing which side effects to expect can help
>> decide how best to deal with them.

Signature

Posted via a free Usenet account from http://www.teranews.com

MAS - 22 Jan 2007 06:09 GMT
Here are two publications describing the trial.

Trial of Chemotherapy plus Hormonal Therapy as Initial Treatment for
Unresectable / Metastatic Adenocarcinoma of the Prostate
H. Henary, R.J. Amato; The Methodist Hospital/The Methodist Hospital
Research Institute/Genitourinary Program, Houston, TX

Background: Chemotherapy is a setting of hormone refractory prostate cancer
has shown palliative benefit especially with substantial PSA decline
strongly suggesting that disease modifying potential exists. Recently,
chemotherapy is beginning to show a survival advantage. The stage is set for
chemotherapy given earlier in a disease course. As a working hypothesis, we
suspect that the transformation from an androgen-dependent to an
androgen-independent phenotype is mediated by the expansion of an
androgen-independent clone already present at the time of androgen
deprivation. If this model is correct, then it would be desirable to bring
treatment to bear on the androgen-independent component when the
corresponding tumor burden is minimal. Thus, we view the
androgen-independent component as analogous to "microscopic residual" or
"micro-metastatic" disease for which adjuvant chemotherapy has shown to be
effective in other contexts.
Methods: Each course of chemotherapy lasts for 8 weeks. Patients were
treated in weeks 1, 3, and 5 with doxorubicin 20 mg/m2 as a 24-hour
intravenous infusion on the first day of every week in combination with
ketoconazole 400 mg orally 3 times a day daily for 7 days. In weeks 2, 4,
and 6, treatment consisted of paclitaxel 100 mg/m2 intravenously on the
first day of every week in combination with estramustine 280 mg orally 3
times a day for 7 days. After completion of 3 courses of chemotherapy,
hormone management [medical castration plus casodex (at the completion of
chemotherapy)] is initiated at the start of chemotherapy and for a total of
24 months.
Results: Nineteen men have been enrolled with a median age of 63 (48-76).
Fifty percent of the men had no prior local therapy, while the other 50%
either failed surgery, radiation therapy, or surgery plus radiation therapy.
Fifty-nine percent of the men had Gleason 7, 12%/8, 24%/9, and 5%/10.
Thirty-five patients presented with bone metastasis and 50% presented with
nodal involvement. The median PSA reduction to date has been 95.6%.
Conclusion: Enrollment is ongoing. Further information regarding PSA
response, associated radiographic response, and toxicity will be presented.

Trial of Chemotherapy (CHT) Plus Hormonal Therapy An Initial Treatment for
Prostate Cancer (PC)
Maushumi Karediy, Tung Shu, Muhammed Khan and Robert Amato
The Methodist Hospital Research Institute, Genitourinary Oncology Center
Houston, Texas
Background: The delivery of CHT in a setting of androgen-independent (AI) PC
has demonstrated: survival benefit associated with a PSA decline and
tolerable toxicity, thus strongly suggesting that disease modifying
potential exists. Preclinical data supports the benefit of simultaneous CHT
and androgen deprivation (AD). The stage is set for CHT to be given earlier
in men with PC. Data suggests a transformation from an androgen-dependent to
an AI phenotype is mediated by the expansion of an AI clone already present
at the time of AD. If this model is correct, it would be feasible to bring
CHT up front when the corresponding tumor burden is minimal. Methods: A
course of CHT is defined as 8 weeks (6 on/2 off). The therapy consists of
weeks 1, 3, and 5 with adriamycin 20 mg/m2 as a 24 hour intravenous infusion
on the first day of every week in combination with ketoconazole 400 mg
orally 3 times a day, daily for 7 days. Weeks 2, 4, and 6 treatment
consisted of docetaxel 35 mg/m2 intravenously over 1 hour on the first day
of every week in combination with estramustine 280 mg orally 3 times a day,
daily for 7 days. Hormone therapy, GnRH antagonist, is initiated within the
first 6 months of starting CHT. Following the completion of 3 courses of
CHT, the addition of casodex occurs. Hormone management then continues for a
total of 24 months, and then is discontinued. Patients (pts) are followed
every 12 weeks with a PSA, testosterone and routine laboratory evaluation.
For those men who have had a PSA recurrence, hormone therapy will be
reinitiated. Results: 31 men have been enrolled to date. 61% percent of the
men had no prior local therapy, while the other 39% had surgery, radiation
therapy or both. 3% had a gleason 6, 45%/7, 26%/8, 23%/9 and 3%/10. 64% of
the men presented with bone and/or nodal metastases. Baseline median PSA was
12.7 (1.1-1065.5). The median PSA reduction to date has been 96% with
associated nodal and bone scan improvement. Conclusion: Enrollment is
ongoing. Information regarding PSA response, radiographic outcome, toxicity
and results of men who are discontinuing hormones will be presented.

> Gourd,
>
[quoted text clipped - 190 lines]
>>> sleepiness, and confusion. Knowing which side effects to expect can help
>>> decide how best to deal with them.
J - 22 Jan 2007 09:02 GMT
> I know that this is a terrible disease and a fear of bones mets is
> overwhelming. Excellent summation, however, I do want to point out that I
[quoted text clipped - 7 lines]
>
> Gourd Dancer

Sounds like you had arthritis (inflammation).
Chemotherapy has anti-inflammatory properties.
You'd have known by now, if it was bone mets, because chemotherapy doesn't stop bone mets from spreading.  Think
about it. If it did, Lori's husband and many others would be alive today.
J
kh - 22 Jan 2007 13:17 GMT
> > I know that this is a terrible disease and a fear of bones mets is
> > overwhelming. Excellent summation, however, I do want to point out that I
[quoted text clipped - 5 lines]
> > My mets disappeared with the January 1995 scan. I have had seven scand since
> > then and still am "all clear."

He means 2004 and 2005.

> > Gourd Dancer
>
> Sounds like you had arthritis (inflammation).
> Chemotherapy has anti-inflammatory properties.
> You'd have known by now, if it was bone mets, because chemotherapy doesn't stop bone mets from spreading.  Think
> about it. If it did, Lori's husband and many others would be alive today.

This may be different.  MAS posted his PSA log and it shows a
shockingly active cancer, doubling in 30 days.  Chemotherapy doesn't
stop the typical prostate cancer because it is so slow growing.

His mets were like a raging fire compared to typical cancers.  Maybe,
just maybe, this variation can be treated with chemotherapy.

Donno.

-kh
MAS - 25 Jan 2007 05:30 GMT
They were mets....

>> I know that this is a terrible disease and a fear of bones mets is
>> overwhelming. Excellent summation, however, I do want to point out that I
[quoted text clipped - 16 lines]
> about it. If it did, Lori's husband and many others would be alive today.
> J
dave perry - 21 Jan 2007 21:47 GMT
> 3. Don't worry about becoming addicted to pain medication. The most common
> reason that doctors are afraid to prescribe strong pain medications and
> that people are afraid to take them is fear of addiction. But that's
> mostly because people don't understand the differences between addiction,
> physical dependence, and tolerance.

Another reason is that the DEA monitors the amounts of narcotic-like
drugs prescribed by each physician.  If a doctor goes over his
allotment - a bit like claiming too many deductions on your income tax
for your income status - the doc has to explain (is audited).  Some
doctors don't give a damn and prescribe what's needed, others are more
cautious sometimes to the detriment of their patients.

Always remember, there is no pain that can't be subdued by sufficient
medication.  The question is how conscious does the patient want to be?
Also, patients and their families have to be told that large amounts
of these meds can hasten death again causing doctors to be cautious
since they can, and often are, sued for killing a patient.  As far as
addiction is concerned, that should be the last concern of anyone in or
approaching hospice-like conditions.  If I may be insensitive for a
moment, it's like a condemned man requesting that his last meal before
execution be low sodium because he has to watch his blood pressure.
Dave Perry
I.P. Freely - 21 Jan 2007 22:28 GMT
>  there is no pain that can't be subdued by sufficient
> medication.  The question is how conscious does the patient want to be?
>  Also, patients and their families have to be told that large amounts
> of these meds can hasten death again causing doctors to be cautious
> since they can, and often are, sued for killing a patient.

Exactly why it's critical that terminal cancer patients -- and anyone
who could get hit by a bus tomorrow -- should have filed copies of their
 terminal care preferences (hell, DEMANDS) with those doctors, the
hospital administration, the pt's family and lawyer . . .  and maybe the
local bus lines. Without that level of exposure and legality, many
physicians lean towards liability risks and Hippocratic oaths rather
than pt's wishes.

I want my wife, and if necessary her lawyer, standing by my bedside
waving my properly executed power of attorney, advanced directive, and
names and addresses of that doctor's children (that part's a joke,
folks) in my doc's face over my pain-wracked body. And when the doc
says, "large amounts of these meds can hasten death", I want both wife
and lawyer shouting in unison, " _*DUH!!!*_; What's your point?"

Unless, of course, my lawyer's hand is on my wife's a.s and I'm just
sleeping off a day of heavy windsurfing.

I.P.
LarryS - 22 Jan 2007 02:17 GMT
[snip]

> Unless, of course, my lawyer's hand is on my wife's a.s and I'm just
> sleeping off a day of heavy windsurfing.

ROTFLMAOWTIME (Rolling on the floor laughing my a.s off, with tears in
my eyes)
 
Sign In
Join
My Latest Posts
My Monitored Threads
My Blog
My Photo Gallery
My Profile
My Homepage

Start New Thread
Enable EMail Alerts
Rate this Thread



©2008 Advenet LLC   Privacy Policy - Terms of Use
This website includes both content owned or controlled by Advenet as well as content owned or controlled by third parties.